Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

606.55INR
18 Sep 2014
Price Change (% chg)

Rs8.25 (+1.38%)
Prev Close
Rs598.30
Open
Rs593.00
Day's High
Rs608.45
Day's Low
Rs591.90
Volume
802,286
Avg. Vol
1,105,626
52-wk High
Rs667.60
52-wk Low
Rs302.00

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 0.66
Market Cap (Mil.): Rs253,687.20
Shares Outstanding (Mil.): 424.01
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): -- 32.66 33.47
EPS (TTM): -20.63 -- --
ROI: -- 18.15 17.39
ROE: -- 18.86 18.25
Search Stocks

India's Ranbaxy says U.S. authorities seek information on pricing data

MUMBAI - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program.

17 Sep 2014

India's Ranbaxy says US authorities seek information on pricing data

MUMBAI, Sept 17 - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program.

17 Sep 2014

Epirus, Ranbaxy win India approval for arthritis drug copy

REUTERS - Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

16 Sep 2014

Epirus, Ranbaxy win India approval for arthritis drug copy

- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

16 Sep 2014

Epirus, Ranbaxy win India approval for arthritis drug copy

Sept 15 - Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

16 Sep 2014

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others

NEW DELHI/MUMBAI - U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations.

15 Sep 2014

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others

NEW DELHI/MUMBAI, Sept 15 - U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.

15 Sep 2014

Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor

REUTERS - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor.

13 Sep 2014

Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor

(Reuters - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor.

13 Sep 2014

UPDATE 1-Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor

Sept 12 (Reuters - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor.

13 Sep 2014

Earnings vs. Estimates

Search Stocks